Skip to content
  • About us
  • Our focus
  • Case studies
  • Our people
  • Our portfolio
  • Contact
Menu
  • About us
  • Our focus
  • Case studies
  • Our people
  • Our portfolio
  • Contact
  • About us
  • Our focus
  • Case studies
  • Our people
  • Our portfolio
  • Contact
Menu
  • About us
  • Our focus
  • Case studies
  • Our people
  • Our portfolio
  • Contact

Curalogic

/ Exited / By Dev 1

Curalogics focused on creating first in class immune therapeutics, with their lead asset targeting grass pollen allergy.

 

History

Liquidated

Related companies

  • All4
  • Exited
  • Private
  • Public
Private

Oxular

Biotech and Drug Delivery

February 2, 2023
Private

JenaValve

Medtech

February 2, 2023
Public

Sonendo

Medtech

February 2, 2023
Public

Sequana Medical

Medtech

February 2, 2023
← Previous Post
Next Post →
Terms & conditions
Cookie policy
Privacy policy

Registered in England No. 3941653 | VAT No. GB 765 3567 96

© 2017 Rosetta Capital Limited | Authorised and regulated by the Financial Conduct Authority

Website by Instinctif Partners

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Rosetta Capital
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.